Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07135219) titled 'A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy' on Aug. 1.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Peking University First Hospital

Condition: Immunoglobulin A Nephropathy (IgAN)

Intervention: Drug: Biological: cizutamig

Recruitment Status: Recruiting

Phase: Early Phase 1

Date of First Enrollment: July 16, 2025

Target Sample Size: 15

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07135219

Published by HT...